• Vaccine Name: AR2+DMC
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The antigen is a fusion protein AR2, composed of Mycobacterium tuberculosis antigens Ag85B (Rv1886c) and Rv1988 (Wang et al., 2022).
• Ag85B from M. tuberculosis H37Rv gene engineering:
  • Type: Fusion Protein
  • Description: This is used in fusion protein preparation(Wang et al., 2022).
  • Detailed Gene Information: Click Here.
• erm(37) gene engineering:
  • Type: Fusion Protein
  • Description: Use in prepare fusion protein(Wang et al., 2022).
  • Detailed Gene Information: Click Here.
• Preparation: The AR2 fusion protein gene was cloned into a prokaryotic expression vector, expressed in Escherichia coli BL21 (DE3), purified under denaturing conditions using His-tag affinity chromatography, and treated with an endotoxin removal kit to reduce endotoxin levels below 0.1 EU/mL before formulation with adjuvants (Wang et al., 2022).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Host age: 6 weeks old
• Host gender: Female
• Vaccination Protocol: Mice were immunized subcutaneously with AR2-based vaccines every 3 weeks for a total of three doses, using PBS as a negative control and BCG as a positive control, followed by immunological analysis at week 9 (Wang et al., 2022).
• Immune Response: Immunization with AR2, particularly when combined with the DMC adjuvant, induced strong Th1-biased immune responses characterized by elevated IFN-?, TNF-?, IL-2, and iNOS expression, increased numbers of IFN-?-secreting CD4? and CD8? T cells, and higher IgG and IgG2a antibody titers(Wang et al., 2022).
• Description: AR2 enhance Th1-biased immune responses and designed as a booster strategy to improve BCG-induced immunity(Wang et al., 2022).
• Information about this animal model: Mouse Model for TB research